ACRS Aclaris Therapeutics, Inc.

26.43
-0.76  -2.8%
Previous Close 27.19
Open 27.20
Price To book 7.18
Market Cap 566.45M
Shares 21,432,000
Volume 195,780
Short Ratio 7.04
Av. Daily Volume 284,227

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 trial met endpoints - November 15, 2016. NDA filing 1Q 2017.
A-101
Seborrheic keratosis (SK)
Phase 2 data released August 18, 2016. Endpoints met.
A-101
Common warts (verruca vulgaris)

Latest News

  1. Why Aclaris Therapeutics (ACRS) Stock Might be a Great Pick
  2. Aclaris to Present at 35th Annual J.P. Morgan Healthcare Conference
  3. Aclaris Therapeutics Inc (ACRS) Hedge Funds Are Snapping Up
  4. Aclaris Therapeutics Initiates Phase 1 Clinical Trial for ATI-50001, an Investigational JAK Inhibitor, for the Treatment of Alopecia Totalis and Alopecia Universalis
  5. Why Aclaris (ACRS) Could Be Positioned for a Surge
  6. Aclaris Therapeutics (ACRS) Worth Watching: Stock Up 7.5%
  7. Coverage initiated on Aclaris Therapeutics by Leerink Partners
  8. Edited Transcript of ACRS earnings conference call or presentation 3-Nov-16 12:30pm GMT
  9. Aclaris Therapeutics, Inc. :ACRS-US: Earnings Analysis: Q3, 2016 By the Numbers : November 28, 2016
  10. Aclaris Therapeutics to Attend Upcoming Investor Conferences
  11. Aclaris Files for Secondary Offering
  12. ACLARIS THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial St
  13. Pharma company targeting skin disorders plans $91M stock sale
  14. Aclaris Announces Pricing of Public Offering of Common Stock
  15. Why Aclaris Therapeutics, Inc. Stock Is Down Today
  16. Aclaris Announces Proposed Public Offering of Common Stock
  17. Aclaris Announces Phase 3 Results, Will Submit NDA In Q1 2017
  18. ACLARIS THERAPEUTICS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
  19. Aclaris Therapeutics Announces Positive Top-Line Phase 3 Results for A-101 In Treating Seborrheic Keratosis, a Common Undertreated Skin Condition
  20. Aclaris Therapeutics Announces Positive Top-Line Phase 3 Results for A-101 In Treating Seborrheic Keratosis, a Common Undertreated Skin Condition